ATE420102T1 - An der metastase beteiligter faktor und verwendungen dafür - Google Patents

An der metastase beteiligter faktor und verwendungen dafür

Info

Publication number: ATE420102T1
Authority: AT; Austria
Prior art keywords: metastasis; polypeptide; amino acid; extracellular matrix; sequence according
Prior art date: 2002-10-18

Application number

AT03769423T

Other languages

English (en)

Inventor

Anke Klippel-Giese

Joerg Kaufmann

Rolf Schwarzer

Original Assignee

Silence Therapeutics Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-18

Filing date

2003-10-20

Publication date

2009-01-15

2003-10-20 Application filed by Silence Therapeutics Ag filed Critical Silence Therapeutics Ag

2009-01-15 Application granted granted Critical

2009-01-15 Publication of ATE420102T1 publication Critical patent/ATE420102T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Molecular Biology (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Dermatology (AREA)
Oncology (AREA)
Neurology (AREA)
Obesity (AREA)
Physics & Mathematics (AREA)
Hematology (AREA)
Emergency Medicine (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Neurosurgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT03769423T 2002-10-18 2003-10-20 An der metastase beteiligter faktor und verwendungen dafür ATE420102T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP02023384		2002-10-18

Publications (1)

Publication Number	Publication Date
ATE420102T1 true ATE420102T1 (de)	2009-01-15

Family

ID=32103889

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03769423T ATE420102T1 (de)	2002-10-18	2003-10-20	An der metastase beteiligter faktor und verwendungen dafür

Country Status (19)

Country	Link
US (2)	US20060240022A1 (de)
EP (2)	EP1551868B1 (de)
JP (2)	JP4820092B2 (de)
KR (1)	KR101154130B1 (de)
CN (1)	CN100564524C (de)
AT (1)	ATE420102T1 (de)
AU (2)	AU2003278112A1 (de)
BR (1)	BR0315411A (de)
CA (1)	CA2501333A1 (de)
CY (1)	CY1110313T1 (de)
DE (1)	DE60325754D1 (de)
DK (1)	DK1551868T3 (de)
ES (1)	ES2319891T3 (de)
IL (1)	IL167801A (de)
MX (1)	MXPA05004134A (de)
PT (1)	PT1551868E (de)
SI (1)	SI1551868T1 (de)
WO (1)	WO2004035615A2 (de)
ZA (1)	ZA200502483B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7405292B2 (en) *	2002-02-19	2008-07-29	The Children's Hospital Of Philadelphia	Cellular genes regulated by HIV-1 infection and methods of use thereof
DK1527176T4 (en)	2002-08-05	2017-07-03	Silence Therapeutics Gmbh	ADDITIONAL NEW FORMS OF INTERFERRING RNA MOLECULES
DE60325754D1 (de) *	2002-10-18	2009-02-26	Silence Therapeutics Ag	An der metastase beteiligter faktor und verwendungen dafür
US7741299B2 (en) *	2004-08-16	2010-06-22	Quark Pharmaceuticals, Inc.	Therapeutic uses of inhibitors of RTP801
CN100357323C (zh) *	2006-01-05	2007-12-26	清华大学	一种细胞迁移相关蛋白及其编码基因与应用
US7825099B2 (en)	2006-01-20	2010-11-02	Quark Pharmaceuticals, Inc.	Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes
UY30097A1 (es)	2006-01-20	2007-08-31	Atugen Ag	Usos terapeuticos de inhibidores de rtp801
FR2898908A1 (fr)	2006-03-24	2007-09-28	Agronomique Inst Nat Rech	Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence
GB2450840B (en)	2006-05-11	2010-12-29	Quark Pharmaceuticals Inc	Screening Systems Utilizing RTP801
EP2137205A2 (de)	2007-02-26	2009-12-30	Quark Pharmaceuticals, Inc.	Inhibitoren von rtp801 und ihre verwendung bei der behandlung von krankheiten
EP2323695B1 (de)	2008-08-19	2018-12-05	Nektar Therapeutics	Komplexe von small-interfering nukleinsäuren
US8916693B2 (en)	2009-09-17	2014-12-23	Nektar Therapeutics	Monoconjugated chitosans as delivery agents for small interfering nucleic acids
BR112015004747A2 (pt)	2012-09-12	2017-11-21	Quark Pharmaceuticals Inc	moléculas oligonucleotídicas de fita dupla para p53 e métodos de uso das mesmas

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2763958B2 (ja)	1990-06-11	1998-06-11	ネクスターファーマスーティカルズ，インコーポレイテッド	核酸リガンド
EP0934331B1 (de)	1996-08-30	2002-11-27	Jens Peter Fürste	Spiegelselektion und spiegelevolution von nucleinsäuren
US5849902A (en)	1996-09-26	1998-12-15	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
US5989912A (en)	1996-11-21	1999-11-23	Oligos Etc. Inc.	Three component chimeric antisense oligonucleotides
DE19742706B4 (de)	1997-09-26	2013-07-25	Pieris Proteolab Ag	Lipocalinmuteine
EP1071753A2 (de)	1998-04-20	2001-01-31	Ribozyme Pharmaceuticals, Inc.	Nukeinsäure moleküle mit einer neuen chemischen zusammensetzung die fähig sind die expression von gene zu modulieren
US5958773A (en) *	1998-12-17	1999-09-28	Isis Pharmaceuticals Inc.	Antisense modulation of AKT-1 expression
DE19956568A1 (de)	1999-01-30	2000-08-17	Roland Kreutzer	Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
JP2003516114A (ja) *	1999-06-11	2003-05-13	ヒューマンジノームサイエンシーズ，インコーポレイテッド	５０個のヒト分泌タンパク質
US6133032A (en) *	1999-09-09	2000-10-17	Isis Pharmaceutical Inc.	Antisense modulation of PI3 kinase p110 beta expression
WO2003070918A2 (en)	2002-02-20	2003-08-28	Ribozyme Pharmaceuticals, Incorporated	Rna interference by modified short interfering nucleic acid
WO2001075164A2 (en)	2000-03-30	2001-10-11	Whitehead Institute For Biomedical Research	Rna sequence-specific mediators of rna interference
US6673545B2 (en) *	2000-07-28	2004-01-06	Incyte Corporation	Prostate cancer markers
AU2002220920A1 (en) *	2000-12-08	2002-06-18	Oxford Biomedica (Uk) Limited	Method for identification of genes involved in specific diseases
WO2003010205A1 (en) *	2001-07-26	2003-02-06	Duke University Medical Center	Genes induced by hypoxia
CN102220423A (zh) *	2002-08-20	2011-10-19	千年药品公司	用于鉴定,评估,预防和治疗子***的组合物,试剂盒及方法
DE60325754D1 (de) *	2002-10-18	2009-02-26	Silence Therapeutics Ag	An der metastase beteiligter faktor und verwendungen dafür
US7741299B2 (en) *	2004-08-16	2010-06-22	Quark Pharmaceuticals, Inc.	Therapeutic uses of inhibitors of RTP801

2003
- 2003-10-20 DE DE60325754T patent/DE60325754D1/de not_active Expired - Lifetime
- 2003-10-20 WO PCT/EP2003/011604 patent/WO2004035615A2/en active Application Filing
- 2003-10-20 ES ES03769423T patent/ES2319891T3/es not_active Expired - Lifetime
- 2003-10-20 MX MXPA05004134A patent/MXPA05004134A/es active IP Right Grant
- 2003-10-20 EP EP03769423A patent/EP1551868B1/de not_active Expired - Lifetime
- 2003-10-20 EP EP09000009A patent/EP2072619A1/de not_active Ceased
- 2003-10-20 CA CA002501333A patent/CA2501333A1/en not_active Abandoned
- 2003-10-20 SI SI200331544T patent/SI1551868T1/sl unknown
- 2003-10-20 CN CNB2003801016454A patent/CN100564524C/zh not_active Expired - Fee Related
- 2003-10-20 BR BR0315411-4A patent/BR0315411A/pt not_active IP Right Cessation
- 2003-10-20 AT AT03769423T patent/ATE420102T1/de active
- 2003-10-20 AU AU2003278112A patent/AU2003278112A1/en not_active Abandoned
- 2003-10-20 US US10/531,726 patent/US20060240022A1/en not_active Abandoned
- 2003-10-20 KR KR1020057006488A patent/KR101154130B1/ko not_active IP Right Cessation
- 2003-10-20 DK DK03769423T patent/DK1551868T3/da active
- 2003-10-20 PT PT03769423T patent/PT1551868E/pt unknown
- 2003-10-20 JP JP2004544275A patent/JP4820092B2/ja not_active Expired - Fee Related
2005
- 2005-03-24 ZA ZA2005/02483A patent/ZA200502483B/en unknown
- 2005-03-31 IL IL167801A patent/IL167801A/en not_active IP Right Cessation
2009
- 2009-03-26 CY CY20091100364T patent/CY1110313T1/el unknown
2010
- 2010-03-10 US US12/721,158 patent/US20100285038A1/en not_active Abandoned
- 2010-11-23 AU AU2010246370A patent/AU2010246370A1/en not_active Abandoned
- 2010-12-22 JP JP2010285811A patent/JP2011125339A/ja active Pending

Also Published As

Publication number	Publication date
US20060240022A1 (en)	2006-10-26
EP1551868B1 (de)	2009-01-07
MXPA05004134A (es)	2005-10-05
BR0315411A (pt)	2005-08-16
US20100285038A1 (en)	2010-11-11
AU2003278112A1 (en)	2004-05-04
ES2319891T3 (es)	2009-05-14
DE60325754D1 (de)	2009-02-26
WO2004035615A3 (en)	2004-06-03
JP2011125339A (ja)	2011-06-30
KR20050056244A (ko)	2005-06-14
WO2004035615A2 (en)	2004-04-29
AU2010246370A1 (en)	2010-12-16
JP4820092B2 (ja)	2011-11-24
CA2501333A1 (en)	2004-04-29
EP2072619A1 (de)	2009-06-24
CN100564524C (zh)	2009-12-02
KR101154130B1 (ko)	2012-06-12
EP1551868A2 (de)	2005-07-13
IL167801A (en)	2012-10-31
JP2006520183A (ja)	2006-09-07
CY1110313T1 (el)	2015-01-14
PT1551868E (pt)	2009-04-06
SI1551868T1 (sl)	2009-06-30
CN1705746A (zh)	2005-12-07
DK1551868T3 (da)	2009-04-20
ZA200502483B (en)	2005-11-30

Legal Events

Date

Code

Title

Description

2009-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1551868

Country of ref document: EP

Publication	Publication Date	Title
CY1110313T1 (el)	2015-01-14	Παραγοντας που εμπλεκεται στη μετασταση και οι χρησεις του
Joester et al.	1999	Evidence for combinatorial variability of tenascin-C isoforms and developmental regulation in the mouse central nervous system
Doliana et al.	1999	EMILIN, a component of the elastic fiber and a new member of the C1q/tumor necrosis factor superfamily of proteins
Valenzuela et al.	2001	The salivary apyrase of the blood-sucking sand fly Phlebotomus papatasi belongs to the novel Cimex family of apyrases
Yonemura et al.	2006	Protein composition of silk filaments spun under water by caddisfly larvae
Katoh et al.	2004	Identification and characterization of human HES2, HES3, and HES5 genes in silico
HUP9900078A2 (hu)	1999-04-28	Eljárás O-acetilszerin, L-cisztein és L-cisztein-származékok előállítására
DK289688D0 (da)	1988-05-27	Ekspression af proapolipoprotein a-i.
ATE528398T1 (de)	2011-10-15	Transkriptionsfaktor-gen osnacx aus reis und verwendung davon zur verbesserung der toleranz von pflanzen gegenüber trockenheit und salz
DE69839768D1 (de)	2008-09-04	Rekombinante lactoferrin, verfahren zu ihrer herstellung mittels pflanzen und ihre verwendung
ATE514781T1 (de)	2011-07-15	Nukleinsäuresequenzen, die für proteine in zusammenhang mit abiotischer stressreaktion kodieren, sowie pflanzenzellen und pflanzen mit erhöhter umweltstressverträglichkeit
DE69926729D1 (de)	2005-09-22	Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
ATE198083T1 (de)	2000-12-15	Thermostable nukleinsäure polymerase
CY1107335T1 (el)	2012-12-19	ΝΕΑ ΠΟΛΥΝΟΥΚΛΕΟΤΙΔΙΑ ΚΑΙ ΠΟΛΥΠΕΠΤΙΔΙΑ ΤΟΥ ΓΟΝΙΔΙΟΥ IFNα-17
DE69631540D1 (de)	2004-03-18	Materialien und methoden mit bezug zur identifizierung und sequenzierung des krebs-suszeptilitaetsgens brca2 und dessen anwendungen
NO20024240L (no)	2002-11-08	Nye arylfruktose-1,6-bisfosfataseinhibitorer
DE60328708D1 (de)	2009-09-17	Sol-gel-biosensoren
ATE120494T1 (de)	1995-04-15	Fibronectinbindungsprotein und dessen herstellung.
Fernández et al.	2016	Molecular determinants of negative regulation of the Bradyrhizobium diazoefficiens transcription factor FixK 2
ATE431361T1 (de)	2009-05-15	Verwendung vom transportergen oatp-c zur screening von testsubstanzen
DE602005019421D1 (de)	2010-04-01	Grosstechnisch geeigneter mikroorganismus
ATE362486T1 (de)	2007-06-15	Menschliche, für neurogenin 3 kodierende nukleotidsequenzen
Zocchi et al.	2023	Deciphering the tubulin language: Molecular determinants and readout mechanisms of the tubulin code in neurons
ATE417066T1 (de)	2008-12-15	Modifizierte cdna für hohe expressionsniveaus von faktor viii und dessen derivaten
DK595187D0 (da)	1987-11-13	Minactivin og fremgangsmaade til fremstilling deraf